Neonc Technologies (NASDAQ:NTHI) CEO Thomas Chen Acquires 5,242 Shares

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) CEO Thomas Chen acquired 5,242 shares of Neonc Technologies stock in a transaction on Monday, September 14th. The shares were bought at an average cost of $3.81 per share, with a total value of $19,972.02. Following the completion of the purchase, the chief executive officer owned 24,503 shares in the company, valued at $93,356.43. The trade was a 27.22% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link.

Neonc Technologies Stock Performance

Neonc Technologies stock opened at $3.31 on Wednesday. The business has a 50 day simple moving average of $4.04 and a 200-day simple moving average of $5.27. Neonc Technologies Holdings, Inc. has a 12 month low of $3.01 and a 12 month high of $12.99.

Neonc Technologies (NASDAQ:NTHI) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.46).

Key Headlines Impacting Neonc Technologies

Here are the key news stories impacting Neonc Technologies this week:

• Positive Sentiment: Company executives continued buying shares. CEO Amir F. Heshmatpour purchased a combined 87,000 shares across transactions dated September 11, 14 and 15, while CEO Thomas C. Chen bought 10,798 shares and CFO Keithly Garnett purchased 257 shares. The purchases signal that management believes the shares may be undervalued and provide a potential confidence boost for investors. SEC insider purchase filing
• Positive Sentiment: NeOnc is advancing NEO100 toward another regulatory review, while its targeted-delivery platform and oncology programs remain central to the investment story. The company’s lead program is in Phase 2a development for glioblastoma, creating potential upside if clinical and regulatory milestones are achieved. NeOnc regulatory update
• Neutral Sentiment: Analyst opinions remain mixed. Several firms maintain Buy ratings and high price targets, but other services have issued Sell ratings; the reported consensus is Hold. These targets may be especially speculative given NeOnc’s early-stage clinical profile.
• Negative Sentiment: The company recently reported a quarterly loss of $0.58 per share, substantially worse than the consensus loss estimate of $0.12. The earnings miss reinforces concerns about cash usage and the time required to commercialize its therapies.
• Negative Sentiment: Recent financing involving healthcare-focused institutions may provide capital to advance NEO100, but issuing or selling additional shares can dilute existing shareholders. Investors are also likely cautious because NTHI remains well below its longer-term moving averages and has experienced elevated trading volume.

Hedge Funds Weigh In On Neonc Technologies

A number of institutional investors and hedge funds have recently made changes to their positions in NTHI. Bank of America Corp DE increased its holdings in shares of Neonc Technologies by 5.0% in the 1st quarter. Bank of America Corp DE now owns 235,396 shares of the company’s stock valued at $1,650,000 after purchasing an additional 11,108 shares in the last quarter. Westmount Partners LLC boosted its holdings in Neonc Technologies by 355.2% during the second quarter. Westmount Partners LLC now owns 197,178 shares of the company’s stock worth $893,000 after buying an additional 153,858 shares in the last quarter. BlackRock Inc. purchased a new stake in Neonc Technologies during the second quarter worth about $815,000. Finally, Global Retirement Partners LLC acquired a new position in Neonc Technologies during the second quarter worth about $126,000.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on NTHI shares. BTIG Research reissued a “buy” rating and set a $15.00 price target on shares of Neonc Technologies in a report on Tuesday, September 8th. Weiss Ratings raised Neonc Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, August 31st. Wall Street Zen cut Neonc Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Finally, Alliance Global Partners assumed coverage on Neonc Technologies in a research note on Tuesday, May 19th. They set a “buy” rating and a $13.00 target price for the company. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $16.00.

Neonc Technologies Company Profile

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.